Neurocompute Narrative Velocity Map
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative
Velocity Map

Explore the Parkinson’s research intelligence diagram before entering the Neurocompute platform.

NC
Neurocompute
AI Parkinson’s Intelligence Terminal
NARRATIVE VELOCITY ENGINE

Neurocompute

AI-driven Parkinson’s research intelligence platform exploring emerging signals, forgotten papers, and therapeutic patterns across the biomedical literature universe.

Indexed Papers
1,516
AI Scored
984
Ranked Papers
998
Coverage
1.3%
RESEARCH INTELLIGENCE BOARD

Ranked Parkinson’s Papers

1516 results
LAST INGEST 2026-05-29 06:45 PM
E
Quantitative ultrasound radiofrequency analysis for monitoring Parkinson's disease.
PMID 41956318 Published: 2026-04-07 Ingested: 2026-04-28 08:58 PM Neuroscience
AI 45.0
Base 30.8
Rank 29.2
AI Summary

Quantitative ultrasound radiofrequency Nakagami imaging detected increased muscle scattering (higher m parameter) across multiple muscles in Parkinson's patients versus controls, with the gastrocnemius medialis m strongly correlating with disease severity and good diagnostic performance in a small…

Why It Matters

This noninvasive, rapid, low-cost imaging biomarker could provide an objective tool for diagnosis and longitudinal monitoring to improve patient stratification and endpoint sensitivity in clinical studies, although findings are preliminary given the small sample and lack of mechanistic linkage to…

E
Longitudinal Modeling of Rank-based Global Outcome.
PMID 41959649 Published: 2026-04-01 Ingested: 2026-04-28 08:58 PM Statistica Sinica
AI 45.0
Base 30.8
Rank 29.2
AI Summary

The paper presents a robust rank-based longitudinal global percentile outcome and associated regression/estimation methods (including dropout handling and variance estimation) to integrate multiple time-varying endpoints and applies it to a Parkinson’s disease clinical trial.

Why It Matters

This approach improves sensitivity and interpretability for PD trial analyses and risk-factor detection—helpful for trial design, endpoint selection, and translational prioritization—even though it does not identify biological mechanisms or direct therapeutic targets.

E
Task-specific machine learning system for automatic assessment of multi-limb bradykinesia in Parkinson's disease.
PMID 42040335 Published: 2026-01-01 Ingested: 2026-04-28 08:58 PM Frontiers in neuroscience
AI 45.0
Base 30.8
Rank 29.2
AI Summary

Developed a task-specific machine learning system with wearable sensors to automatically score multi-limb bradykinesia (MDS‑UPDRS III tasks) showing promising accuracy (peak F1≈0.87) in a small cohort (21 PD, 8 controls).

Why It Matters

Delivers an objective, automated bradykinesia measurement that could standardize assessments and improve outcome measures and monitoring in clinical trials and care, but requires larger validation for therapeutic decision-making.

E
Long-term outcomes after caudal zona incerta-forel field ablation: three-year clinical follow-up in advanced Parkinson's disease.
PMID 41972105 Published: 2026-01-01 Ingested: 2026-04-28 08:58 PM Frontiers in aging neuroscience
AI 45.0
Base 30.8
Rank 29.2
AI Summary

Prospective study of 10 advanced unilateral tremor-rigid PD patients treated with stereotactic radiofrequency ablation of the caudal zona incerta and Fields of Forel showed very large, sustained UPDRS III improvements over 3 years with minimal transient adverse effects.

Why It Matters

Provides clinically relevant evidence that infrathalamic ablation can be a durable, relatively safe alternative to DBS in selected patients or low-resource settings, but offers little mechanistic or biomarker insight for pharmacologic therapeutic discovery.

E
Insole-Derived Plantar Pressure Variability Reveals Dual-Task Gait Differences in Early-Stage Parkinson's Disease.
PMID 41970941 Published: 2026-01-01 Ingested: 2026-04-28 08:58 PM IEEE journal of translational engineering in health and medicine
AI 45.0
Base 30.8
Rank 29.2
AI Summary

Sensor-equipped insoles measuring plantar pressure detect subtle and dual-task-specific gait abnormalities in early-stage Parkinson's disease that conventional spatiotemporal metrics largely miss.

Why It Matters

Validating an affordable, clinic-ready biomarker that is more sensitive to early and cognitively-challenged gait deficits could improve early detection, patient stratification, monitoring of progression, and outcome measurement in PD therapeutic trials.

E
Muscle Network of Parkinson's Gait: A 12-Month Longitudinal Analysis Before and After Deep Brain Stimulation Surgery.
PMID 41955137 Published: 2026-01-01 Ingested: 2026-04-28 08:58 PM IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society
AI 45.0
Base 30.8
Rank 29.2
AI Summary

Graph-theory analysis of inter-muscular coherence from instrumented gait EMG shows PD patients have increased muscle network density and reduced modularity versus controls, which move toward normal levels 12 months after bilateral subthalamic DBS and correlate with UPDRS-III improvement.

Why It Matters

Offers a noninvasive, quantitative network-level biomarker for gait motor control and DBS response that could be used to monitor treatment efficacy or as an objective endpoint in clinical studies, though it provides limited new mechanistic or target-discovery insight.

E
Molecular chaperones mediated proteostasis depletion: A cause of neurodegeneration?
PMID 41904003 Published: 2026-01-01 Ingested: 2026-04-28 08:58 PM Advances in protein chemistry and structural biology
AI 45.0
Base 30.8
Rank 29.2
AI Summary

A focused review examining how chaperones (Hsp90, Hsp110, Hsp27, and DJ-1) regulate proteostasis and how their dysfunction may contribute to neurodegenerative diseases including Parkinson's, with discussion of mechanisms for folding, aggregation prevention, and degradation pathways.

Why It Matters

Highlights chaperone-based mechanisms (including the PD-linked DJ-1 and mitoprotection) that suggest actionable targets for modulating proteostasis, but remains a conceptual review with limited new experimental or translational data.

AI Summary

Using in vivo negligible-depletion SPME in a 6‑OHDA rat model, the study quantified free and total anandamide (AEA) and 2‑AG, finding significantly elevated striatal free AEA in lesioned animals while 2‑AG was undetectable in vivo.

Why It Matters

Provides a minimally perturbing in vivo method to measure biologically active endocannabinoids and highlights AEA as a candidate early PD biomarker, supporting translational biomarker development though it offers limited immediate therapeutic mechanistic insight.

E
Dual Oscillatory Signatures in Pallidal Circuits Underlie Symptom Complexity in Huntington's Disease Patients.
PMID 41937711 Published: 2026-04-06 Ingested: 2026-04-28 08:58 PM Movement disorders : official journal of the Movement Disorder Society
AI 42.0
Base 30.8
Rank 29.2
AI Summary

This study reports that Huntington's disease patients exhibit dual pallidal oscillatory signatures—posterior GP theta (2–8 Hz) linked to hyperkinesia and high beta (20–30 Hz) linked to hypokinesia—mapped to distinct pallidal subregions and indirect/direct pathway connectivity and proposed as…

Why It Matters

Although HD-focused, the paper provides circuit-level biomarkers, pallidal subregion mapping, and DBS-targeting insights that are translatable to Parkinson's therapeutics for improving stimulation strategies and monitoring motor-state biomarkers.

E
AI 42.0
Base 30.8
Rank 29.2
AI Summary

Longitudinal analysis in PPMI shows accelerated epigenetic aging in blood associates with worsening tremor phenotypes in Parkinson's disease—particularly in men—while associations with gait, rigidity, and bradykinesia are weaker or absent.

Why It Matters

This supports blood-based epigenetic clocks as candidate biomarkers for monitoring tremor progression and for patient stratification in trials, providing translational value despite limited direct mechanistic or therapeutic targets.

E
Dynamical analysis of a mean firing rate model in Parkinson's disease.
PMID 42028460 Published: 2026-12-01 Ingested: 2026-04-28 08:58 PM Cognitive neurodynamics
AI 40.0
Base 30.8
Rank 29.2
AI Summary

A computational mean firing-rate model incorporating cortex, thalamus and PPN identifies how dopaminergic parameter interactions, synaptic weights, delays and time constants can produce pathological beta-band oscillations in basal ganglia circuits.

Why It Matters

The work highlights circuit-level drivers (cortex–thalamus coupling, STN–GPe loop strength, connection delays, and PPN dynamics) that are actionable targets for neuromodulation or DBS parameter optimization and generates testable quantitative hypotheses, but it lacks molecular mechanisms and in…

E
Altered EEG microstate transition patterns and visual hallucinations in Parkinson's Disease.
PMID 41895342 Published: 2026-06-01 Ingested: 2026-04-28 08:58 PM International journal of psychophysiology : official journal of the International Organization of Psychophysiology
AI 40.0
Base 30.8
Rank 29.2
AI Summary

Resting-state EEG microstate transition patterns (reduced D→B and increased E→F and F→C) differentiate PD patients with visual hallucinations with ~89.5% accuracy.

Why It Matters

Identifies a noninvasive, high-temporal-resolution biomarker of large-scale network imbalance that can help stratify patients, monitor hallucinatory risk, and inform network-targeted interventions (e.g., neuromodulation) though it lacks direct molecular or therapeutic mechanisms.

E
Machine learning classification of early-stage Parkinson's disease using sit-to-walk biomechanical features.
PMID 41912640 Published: 2026-03-30 Ingested: 2026-04-28 08:58 PM Scientific reports
AI 40.0
Base 30.8
Rank 29.2
AI Summary

Using 3D motion capture, force plates, and EMG from 106 participants performing a sit-to-walk task, the authors identified three biomechanical features (mean COM speed, anteroposterior CoP–COM displacement during gait-initiation, and forward thoracic range of motion) and trained a random forest…

Why It Matters

The work offers objective, noninvasive biomechanical biomarkers and a proof-of-concept ML screening tool that could aid earlier detection and functional monitoring of PD, though it does not provide molecular targets or direct therapeutic interventions.

E
Opicapone in Parkinson's patients with motor fluctuations: clinical assessments and patient-reported outcomes from the OPTI-ON study.
PMID 42016531 Published: 2026-01-01 Ingested: 2026-04-28 08:58 PM Clinical parkinsonism & related disorders
AI 40.0
Base 30.8
Rank 29.2
AI Summary

A 6-month prospective, open-label US observational study found add-on opicapone improved motor and non-motor fluctuations and was generally well tolerated in Parkinson's patients with OFF episodes.

Why It Matters

Supports real-world symptomatic efficacy and tolerability of opicapone as a levodopa adjunct—useful for clinical practice and therapeutic positioning but offering limited mechanistic or novel discovery insights for Parkinson's drug development.

E
Association of neurogenic orthostatic hypotension with cognitive decline in Parkinson's disease: a longitudinal cohort study.
PMID 41908284 Published: 2026-01-01 Ingested: 2026-04-28 08:58 PM Frontiers in neurology
AI 40.0
Base 30.8
Rank 29.2
AI Summary

In a retrospective longitudinal cohort, Parkinson's patients with baseline neurogenic orthostatic hypotension experienced significantly faster decline in global and multiple domain-specific cognitive scores (MoCA) over time, without accelerated motor or nonmotor symptom progression.

Why It Matters

This identifies nOH as a clinically assessable prognostic biomarker that could help stratify PD patients for cognitive-risk, monitoring, and trials and suggests autonomic/cerebral-perfusion pathways as potential but currently underexplored therapeutic targets.

E
Depression in Parkinson's disease: prevalence and impact on oculomotor features.
PMID 41895089 Published: 2026-06-01 Ingested: 2026-04-28 08:58 PM Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
AI 38.0
Base 30.8
Rank 29.2
AI Summary

This study shows PD patients with depression exhibit pronounced oculomotor impairments—longer initiation times, slower smooth pursuit, and reduced saccade velocities—with average saccade velocity predicting depression (AUC 0.919) and negatively correlating with HAMD scores.

Why It Matters

Identifies a noninvasive, objective biomarker (reduced saccade velocity) that could improve screening, stratification, and monitoring of depressive symptoms in PD—useful for clinical care and trial design—though it does not directly reveal therapeutic targets.

E
Early Symptoms of Language Disorders in Bilingual Parkinson's Disease Patients: Microstructural and Social-Pragmatic Narrative Elements.
PMID 42017696 Published: 2026-04-22 Ingested: 2026-04-28 08:58 PM Journal of speech, language, and hearing research : JSLHR
AI 38.0
Base 30.8
Rank 29.2
AI Summary

This study reports that bilingual early-stage idiopathic Parkinson's patients exhibit microstructural language deficits (lower MLU-M, more morphological errors and verbal fragmentation), pragmatic changes (fewer enrichment expressions, more exclamations), and altered prosody, with bilingualism…

Why It Matters

Offers a noninvasive discourse-level behavioral biomarker for early/subclinical PD detection and patient stratification that could inform clinical assessments and outcome measures in trials, though it does not provide molecular mechanisms or direct therapeutic targets.

E
Differences in total electrical energy delivered after deep brain stimulation among clinical motor subtypes of Parkinson's disease.
PMID 42030627 Published: 2026-04-17 Ingested: 2026-04-28 08:58 PM Clinical neurology and neurosurgery
AI 38.0
Base 30.8
Rank 29.2
AI Summary

This prospective cohort study found that total electrical energy delivered (TEED) and programming parameters after subthalamic nucleus DBS differ by Parkinson's motor subtype, with tremor-dominant patients requiring the highest stimulation energy, followed by PIGD and mixed subtypes.

Why It Matters

Findings support subtype-specific DBS programming to improve clinical efficacy and energy efficiency (battery life and device management), but the study offers limited direct insight for pharmacological target discovery or neuroprotective strategies.

E
CACNA1C-Related Channelopathy Presenting With Adult-Onset Combined Dystonia-Parkinsonism: A Novel Neurological Presentation.
PMID 41978253 Published: 2026-04-13 Ingested: 2026-04-28 08:58 PM American journal of medical genetics. Part A
AI 38.0
Base 30.8
Rank 29.2
AI Summary

Single-case report linking a heterozygous truncating CACNA1C variant to adult-onset combined dystonia–parkinsonism with improvement after GPi-DBS.

Why It Matters

Points to Cav1.2 (CACNA1C) haploinsufficiency as a possible, clinically actionable contributor to movement disorders—supporting genetic testing and DBS consideration—but single-case data limit immediate translational impact for Parkinson's-targeted therapies.

E
Prognosis in Parkinson's Disease: An Individual Patient Data Meta-Analysis of Six European Incidence Cohorts.
PMID 41964342 Published: 2026-04-11 Ingested: 2026-04-28 08:58 PM Movement disorders : official journal of the Movement Disorder Society
AI 38.0
Base 30.8
Rank 29.2
AI Summary

Individual-patient meta-analysis of six European population-based PD incidence cohorts (n=883) reports median survival of 9.4 years, median time to postural instability/functional dependency ~7.4 years, ~50% dementia by 10 years, and identifies older age, higher MDS-UPDRS-III, lower MMSE, GBA…

Why It Matters

While not mechanistic, the study provides robust, less-biased prognostic data and genetic predictors (GBA, APOE e4) that are valuable for clinical trial design, patient stratification/enrichment, and prioritizing subgroups for targeted therapeutic strategies.

AI Summary

In a small observational secondary analysis of PKG wearable data (n=25–30 complete cases), increased percent time in dyskinesia tended to associate with less improvement in total MDS‑UPDRS over routine treat‑to‑target care, but the adjusted effect was borderline (β=0.25 per 1% PTD, p=0.064) and…

Why It Matters

Indicates wearable-derived dyskinesia burden may serve as a pragmatic digital biomarker to monitor and potentially guide PD treatment, offering translational clinical utility if confirmed in larger prospective studies.

E
Anthracene-Modified Nanoporous Silica Nanoparticles for ATP Detection and Salivary Diagnostics in Parkinson's Disease.
PMID 41953584 Published: 2026-04-03 Ingested: 2026-04-28 08:58 PM ACS applied nano materials
AI 38.0
Base 30.8
Rank 29.2
AI Summary

The authors developed an anthracene-functionalized MCM-41 nanoparticle fluorescence sensor array to detect ATP and used pattern-recognition (LDA, ANN) on saliva samples to discriminate Parkinson's disease patients from controls (n=24 vs 23) with 73.7% sensitivity and 83.3% specificity.

Why It Matters

Offers a noninvasive, ATP-focused salivary biomarker assay reflecting metabolic/mitochondrial perturbations relevant to PD that could support patient stratification or monitoring, but it has limited immediate therapeutic discovery impact and requires larger clinical validation.

E
Plasma Neurofilament Light Chain as a Biomarker for Motor Progression and Disease Milestones in Multiple System Atrophy: An Updated Prospective Cohort Study.
PMID 41912379 Published: 2026-03-30 Ingested: 2026-04-28 08:58 PM Movement disorders : official journal of the Movement Disorder Society
AI 38.0
Base 30.8
Rank 29.2
AI Summary

In a 4-year prospective cohort of 93 patients with multiple system atrophy, higher baseline plasma neurofilament light chain (NfL) predicted faster motor decline, earlier attainment of disability milestones and increased mortality, whereas longitudinal NfL levels declined in mid-to-late disease and…

Why It Matters

Establishes a blood-based prognostic biomarker useful for early-stage MSA patient stratification in clinical trials and outcome prediction—valuable for translational and trial design but offering limited direct therapeutic targets for Parkinson's drug discovery.

E
Lower serum uric acid levels as a risk factor for depression in prodromal Parkinson's disease: a cohort study.
PMID 42046555 Published: 2026-01-01 Ingested: 2026-04-28 08:58 PM Open life sciences
AI 38.0
Base 30.8
Rank 29.2
AI Summary

In a 5-year longitudinal analysis of prodromal PD participants from PPMI (61 with complete follow-up), lower baseline serum uric acid independently predicted incident depression (HR=0.776) after adjustment, alongside higher MDS‑UPDRS I scores.

Why It Matters

This provides a prospective biomarker for early identification of depression risk in prodromal PD and implicates oxidative‑stress/urate pathways as mechanistically relevant and potentially targetable, though causality and therapeutic utility remain unproven and sample size is limited.

E
AI 36.0
Base 30.8
Rank 29.2
AI Summary

In a 12‑week randomized, double‑blind, placebo‑controlled trial of a nine‑strain probiotic in 61 people with PD and clinically significant anxiety, the probiotic did not reduce anxiety versus placebo, produced no detectable changes in gut microbiota composition or systemic inflammatory markers, but…

Why It Matters

The negative primary outcome limits immediate therapeutic relevance, but the modest cognitive signal and gut–brain axis approach justify larger, mechanistically focused trials to assess microbiome‑based strategies for cognitive symptoms in PD.

Previous
Page 26 of 61
Next
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic
Full Neurocompute Infographic